Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) is anticipated to release its Q3 2026 results on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.
Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.19. On average, analysts expect Reviva Pharmaceuticals to post ($2.96) EPS for the current fiscal year and ($1.26) EPS for the next fiscal year.
Reviva Pharmaceuticals Stock Performance
Shares of NASDAQ:RVPH opened at $0.38 on Wednesday. The business’s fifty day moving average price is $0.47 and its two-hundred day moving average price is $1.34. The stock has a market cap of $4.92 million, a PE ratio of -0.20 and a beta of 0.61. Reviva Pharmaceuticals has a one year low of $0.26 and a one year high of $15.40.
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system, inflammatory and cardiometabolic disorders. The company’s lead product candidate is brilaroxazine, formerly known as RP5063, a novel serotonin-dopamine activity modulator being developed for psychiatric and neurological conditions. Brilaroxazine has been evaluated in clinical studies for schizophrenia and has also been investigated for other potential indications, including bipolar disorder, major depressive disorder, dementia-related behavioral symptoms and pulmonary arterial hypertension.
Read More
- Five stocks we like better than Reviva Pharmaceuticals
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
